QX-008N

N/A

Report date: 2026/05/26 20:00:28

Base Information

Drug NameQX-008N
Drug Alias Name重组人源化抗TSLP单克隆抗体注射液QX-008NQX008NJKN-2401JKN2401 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionThymic stromal lymphopoietin inhibitors
TargetsThymic stromal lymphopoietin
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Pulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesQyuns Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesQyuns Therapeutics Co LtdJoincare Pharmaceutical Group Industry Co LtdLivzon Mabpharm Inc
Inactive CompaniesN/A
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Pulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A